Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00879684 · ClinicalTrials.gov registry record · Phase 1
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00879684: Completed Phase 1 study, sponsored by Pfizer.
NCT00879684 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00879684, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
Primary Outcome
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to
Interventions
- BIOLOGICAL CVX-060
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
What the finished NCT00879684 record still lists
NCT00879684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which CVX-060 is the first listed.
NCT00879684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00879684 about?
NCT00879684 is a clinical study titled "Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors". The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
What is the current status of trial NCT00879684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2008-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00879684?
The interventions under investigation include: CVX-060 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00879684?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00879684's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia